Identification of CD44 as a Reliable Biomarker for Glioblastoma Invasion: Based on Magnetic Resonance Imaging and Spectroscopic Analysis of 5-Aminolevulinic Acid Fluorescence
Akihiro Inoue(Ehime University), Takeharu Kunieda(Ehime University), Hideaki Watanabe(Showa University Northern Yokohama Hospital), Takanori Ohnishi(Saiseikai Matsuyama Hospital), Junya Tanaka(Ehime University), Hajime Yano(Ehime University), Masahiro Nishikawa(Ehime University), Mashio Taniwaki(Ehime University Hospital), Kosuke Kusakabe(Ehime University), Daisuke Yamashita(University of Alabama at Birmingham), Shirabe Matsumoto(Ehime University), Satoshi Suehiro(Ehime University), Hisaaki Takahashi(Hokuriku University), Riko Kitazawa(Ehime University Hospital), Yoshihiro Ohtsuka(Ehime University), Seiji Shigekawa(Ehime University)
Cited by 12
Related Papers
Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma
|Stem Cells International|2018|68
Targeting glioma-initiating cells via the tyrosine metabolic pathway
|Journal of neurosurgery|2020|42
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
|Cancer Medicine|2021|26